课题基金 / 基金详情

STEROID ANATAGONISTS

STEROID ANATAGONISTS
类固醇拮抗剂
批准号:
3942053
负责人:
G P CHROUSOS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

G P CHROUSOS的其他基金

相关文献

中文摘要
翻译
存在临床上有用的雌激素、雄激素和雌激素受体拮抗剂。 盐皮质激素 糖皮质激素拮抗剂 已经发现了具有潜在临床用途的孕激素 就在最近 该项目的目标是开发和 研究作用的分子机制和人类 这两类拮抗剂的应用 类固醇. 最初,我们证明糖皮质激素拮抗剂可以 通过对甾体C的11位进行修饰而开发的 环糖皮质激素。 我们测试了一种糖皮质激素的原型- 最近由Alzheel开发的抗肿瘤蛋白拮抗剂(RU 486), UCLAF。 这种化合物对人体有很强的亲和力 糖皮质激素和孕酮受体,并且没有激动剂 在小动物实验中的作用 给予非人灵长类动物或人RU 486长期升高 血浆促肾上腺皮质激素、皮质醇和精氨酸加压素,所有变化 可通过先前给予糖皮质激素预防 (地塞米松)。 这表明抗糖皮质激素可能是 用于激发下丘脑-垂体-肾上腺轴, 需要在患有该轴疾病的患者中进行临床测试。 重症库欣综合征的抗糖皮质激素治疗 异位ACTH分泌或肾上腺皮质综合征 肿瘤引起缓解的临床表现, 皮质醇过多症 我们已经治疗了7名患者,目前 扩大治疗系列。 在黄体期给予妇女每月一次的剂量, 循环RU 486引起阴道出血。 后续周期 正常持续时间。 这表明单剂量RU 486 可以用来避孕。
英文摘要
Clinically useful antagonists exist for estrogens, androgens, and mineralocorticoids. Antagonists for the glucocorticoids or the progestins with potential clinical usefulness have been discovered only recently. The objective of this project is to develop and study the molecular mechanisms of action and the human applications of the antagonists for both of these classes of steroids. Initially, we proved that glucocorticoid antagonists can be developed by modifications of the 11-position of the steroidal C ring glucocorticoids. Then we tested a prototype glucocorticoid- progestin antagonist (RU 486) developed recently by Roussel- UCLAF. This compound has strong affinities for the human glucocorticoid and progestin receptor and is devoid of agonist effects in small experimental animals. Given to nonhuman primates or man RU 486 prolonged elevations of plasma ACTH, cortisol and arginine vasopressin, all changes preventable by previous administration of a glucocorticoid (dexamethasone). This suggests that antiglucocorticoids could be used for challenging the hypothalamic-pituitary-adrenal axis when clinical testing is required in patients with disorders of this axis. Antiglucocorticoid therapy of patients with severe Cushing's syndrome due to ectopic ACTH secretion or adrenocortical tumors causes remission of the clinical manifestations of hypercortisolism. We have treated 7 patients and are currently enlarging the therapy series. Given to women in single monthly doses during the luteal phase of the cycle RU 486 causes vaginal bleeding. The subsequent cycle is of normal duration. This suggests that single doses of RU 486 could be used for contraception.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
PHYSIOLOGY OF STRESS AND CLINICAL APPLICATIONS OF CORTICOTROPIN RELEASING HORMONE
PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
ENDOCRINE-IMMUNE INTERACTIONS